Table 3 Model performance in predicting early recurrence of pancreatic cancer in the development and test cohorts

Development cohort

Radiomics model

0.73

(0.57–0.84)

0.048^*

0.20

(0.16–0.25)

0.64

(0.50–0.77)

0.75

(0.38–0.96)

0.60

(0.46–0.84)

CR model

0.70

(0.60–0.77)

0.26^*

0.20

(0.18–0.24)

0.70

(0.61–0.76)

0.50

(0.26–0.68)

0.81

(0.66–0.93)

CRR model

0.77

(0.63–0.86)

–

0.19

(0.14–0.24)

0.66

(0.51–0.78)

0.77

(0.49–0.96)

0.61

(0.47–0.84)

Test cohort

Radiomics model

0.69

(0.51–0.85)

0.038^†

0.24

(0.22–0.25)

0.45

(0.43–0.50)

1.00

(1.00–1.00)

0.04

(0.00–0.13)

CR model

0.76

(0.56–0.83)

0.17^†

0.21

(0.20–0.26)

0.70

(0.53–0.78)

0.41

(0.12–0.53)

0.91

(0.78–1.00)

CCR model

0.83

(0.65–0.94)

–

0.20

(0.18–0.24)

0.78

(0.60–0.85)

0.65

(0.29–0.77)

0.87

(0.70–1.00)